G
GC Therapeutics
Synthetic biology solutions programming patient-derived stem cells into any cell type with unmatched efficiency, speed, and scalability
About GC Therapeutics
GC Therapeutics Inc. (GCTx) leverages synthetic biology to reprogram patient-derived stem cells into any desired cell type with unparalleled efficiency, speed, and scalability. This innovative approach allows the company to dictate cell fates in a single step, making it a game-changer in the fields of cell therapies, transplants, and disease-specific cell tailoring. GCTx serves a diverse clientele, including medical researchers, pharmaceutical companies, and healthcare providers, operating primarily in the biotechnology and healthcare markets. The company’s business model revolves around providing customized cell programming solutions and validated cell types for various medical applications. Revenue is generated through service contracts, partnerships, and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 45
- Open positions
- 1
- Dealroom signal
- 78.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2024 | $0 | — | Global Brain Corporation | ↗ |
| SERIES AOther financing | Sep 2024 | $65M | $260M | Cercano Management · Pear Ventures · Andreessen Horowitz · Mubadala Capital | ↗ |
Growth signals
Latest recorded traffic for GC Therapeutics is 4.2K monthly website visits, up 5% over the last three months. GC Therapeutics's team grew 9.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GC Therapeutics in the Cambridge ecosystem
The GC Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Andreessen Horowitz
Humboldt Fund
Series A6 investors entered at this stage
Cormorant Asset Management
Cercano Management
Pear Ventures
Mubadala Capital
Medical Excellence Capital
Global Brain Corporation
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GC Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GC Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









